Mizuho cuts LeonaBio stock price target on financing concerns

Mizuho reduced its price target for LeonaBio (LONA) to $12 from $13, citing financing concerns after warrants expired unexercised. The stock is down 29% this week. Mizuho maintains an Outperform rating, noting progress in the ELAINE-3 study and a supportive investor base. LeonaBio reported Q3 2026 results, confirming trial enrollment completion by year-end 2026. Other analysts also adjusted price targets.

Original reporting
Published Nov 18, 2026, 6:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 7:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LONA
Bearish
high confidence
Mentioned
$LONA
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LONABearishMed
01

Why it matters

Analyst target reductions reflect perceived funding risk, which could depress the share price in the near term.

02

Market read

The downgrade and financing overhang are new information that may influence short‑term trading decisions on LONA.

03

What to watch

Strong cash position and a favorable current ratio may mitigate short‑term risk if new capital is secured.

Relevance 6/10Novelty 6/10Timing: today

Background

LeonaBio reported Q3 2026 results, highlighted progress on its Phase 3 ELAINE‑3 trial, and faced a $146 M warrant expiration that created financing concerns.

Company-level read

Ticker impact

$LONABearishHigh confidence
Context

Mizuho lowered its price target on LeonaBio to $12, citing financing overhang and recent Q3 results.

Expected impact

downward pressure as investors price in the reduced target and cash‑burn risk

Evidence & confidence

The target cut and mention of unexercised warrants signal near‑term funding risk, likely prompting sell‑side activity.

Market effects

Biotech sector may see heightened scrutiny on cash‑burn and financing structures.

US small‑cap biotech investors could adjust exposure.

Limited to investors tracking early‑stage oncology pipelines.

Counterpoint

Despite the target cut, the stock remains far below its 52‑week high, offering a potential upside if financing improves.

Key entities

  • LeonaBio

    NASDAQ‑listed biotech developing lasofoxifene for advanced breast cancer.

  • Mizuho

    Equity research firm that lowered its price target on LeonaBio.

Related articles

$LONAMed

In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3

$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.